Sionna Restructures For CF Trials
Sionna Therapeutics cuts 46 percent of its workforce to prioritize cystic fibrosis drug development.
Anonymous
Key Points
1
The restructuring is expected to be substantially completed by the end of the third quarter of 2026, although related cash payments will continue through the fourth quarter.
2
Sionna is terminating certain clinical, manufacturing and other vendor arrangements as part of winding down the SION-719 add-on program.
3
The planned AscenSION CF trial will be open-label and is expected to switch participants from Trikafta to the SION-451/SION-2222 regimen for 28 days, measuring sweat chloride, safety and pharmacokinetics.
4
Chief Business Officer Caroline Stark Beer’s employment was terminated without cause effective Sept. 15, 2026; Sionna said its CFO would assume the chief business officer title while other senior officers take on additional responsibilities without pay changes.
5
Sionna said its post hoc analysis identified factors that may have complicated interpretation of the SION-719 trial and blunted the impact of NBD1 stabilization; CEO Mike Cloonan said those findings, alongside favorable Phase 1 results for the dual combination, supported advancing SION-451 and SION-2222 into Phase 2a.
Sionna Therapeutics is cutting 46% of its workforce and shelving its SION-719 program to double down on a new cystic fibrosis drug combo Endpoints News. The biotech company will spend $6.4 million on the restructuring but expects to stretch its cash runway into the second half of 2029. The move sets up a Phase 2a trial of SION-451 and SION-2222 starting in early 2027.
The decision follows a setback: SION-719 missed its main trial goal, though post hoc analysis found sweat chloride reductions up to 8.6 mmol/L in a patient subset RTTNews. CEO Mike Cloonan says new data on the dual combo's Phase 1 results convinced leadership to pivot toward the combination approach instead.
From Standalone Drug to Dual Therapy Strategy
Sionna's original SION-719 add-on program tested a single drug added to existing CF treatments Endpoints News. The company terminated vendor agreements and clinical arrangements tied to that program. Leadership reviewed trial data and identified factors that complicated how well the drug worked. The shift to SION-451 plus SION-2222 represents a complete change in therapeutic approach.
The AscenSION CF Trial Design and Timeline
The Phase 2a proof-of-concept trial will be open-label and enroll adults with cystic fibrosis who carry the F508del mutation RTTNews. Patients will switch from Trikafta to the SION-451 and SION-2222 regimen for 28 days. Researchers will measure sweat chloride levels, safety signals, and how the drugs move through the body. The trial is scheduled to start in the first quarter of 2027.
Staff Cuts and Leadership Changes Kick In This Fall
Sionna expects to finish most restructuring by the end of the third quarter of 2026, though cash payments will extend into the fourth quarter Endpoints News. The company terminated Chief Business Officer Caroline Stark Beer effective September 15, 2026. The CFO is assuming the chief business officer role, while other senior leaders take on added duties without salary increases.
Why the Dual Combo Offers a Fresh Opportunity
The SION-719 trial's primary endpoint failure masked promising subset results. Post hoc analysis showed the drug stabilized a protein called NBD1 but faced unexpected obstacles in showing benefit RTTNews. The dual combination of SION-451 and SION-2222 takes a different approach, targeting two mechanisms simultaneously. Leadership believes Phase 1 safety and efficacy data for this combination warrant advancing to a proof-of-concept study.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
29
Reach
46
A
AnonymousAuthor
